Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Standard BioTools Inc (NASDAQ: LAB) was $2.41 for the day, up 3.88% from the previous closing price of $2.32. In other words, the price has increased by $3.88 from its previous closing price. On the day, 2.36 million shares were traded. LAB stock price reached its highest trading level at $2.42 during the session, while it also had its lowest trading level at $2.28.
Ratios:
Our analysis of LAB’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.17 and its Current Ratio is at 4.50. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.05.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, TD Cowen on April 16, 2024, initiated with a Buy rating and assigned the stock a target price of $3.50.
On April 04, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $3.25.
On July 12, 2023, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $4.KeyBanc Capital Markets initiated its Overweight rating on July 12, 2023, with a $4 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 23 ’24 when Casdin Partners Master Fund, L bought 100,000 shares for $2.60 per share. The transaction valued at 260,000 led to the insider holds 46,075,821 shares of the business.
Casdin Partners Master Fund, L bought 150,000 shares of LAB for $387,735 on May 22 ’24. The Director now owns 45,975,821 shares after completing the transaction at $2.58 per share. On May 21 ’24, another insider, Casdin Partners Master Fund, L, who serves as the Director of the company, bought 350,000 shares for $2.56 each. As a result, the insider paid 895,930 and bolstered with 45,825,821 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LAB now has a Market Capitalization of 891509632 and an Enterprise Value of 267928320. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.28 while its Price-to-Book (P/B) ratio in mrq is 1.59. Its current Enterprise Value per Revenue stands at 2.114 whereas that against EBITDA is -3.305.
Stock Price History:
Over the past 52 weeks, LAB has reached a high of $3.16, while it has fallen to a 52-week low of $1.57. The 50-Day Moving Average of the stock is -6.20%, while the 200-Day Moving Average is calculated to be -0.41%.
Shares Statistics:
LAB traded an average of 2.54M shares per day over the past three months and 2114040 shares per day over the past ten days. A total of 383.05M shares are outstanding, with a floating share count of 376.76M. Insiders hold about 1.64% of the company’s shares, while institutions hold 69.54% stake in the company. Shares short for LAB as of 1715731200 were 12094800 with a Short Ratio of 4.76, compared to 1713139200 on 11277340. Therefore, it implies a Short% of Shares Outstanding of 12094800 and a Short% of Float of 6.68.
